Electronic Glycemic Management Systems Versus Conventional Insulin Infusion Protocols in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis of Non-Randomized Studies.

TL;DR

A meta-analysis of seven non-randomized studies found no significant difference between automated electronic glycemic management systems and conventional insulin protocols for treating diabetic ketoacidosis (DKA) in terms of time to resolution or hospital outcomes . The lower recorded hypoglycemia with automated systems may reflect better glucose monitoring rather than genuine clinical superiority.

What the Study Found

Diabetic ketoacidosis is a serious metabolic emergency requiring precise insulin infusion to lower blood glucose and restore acid-base balance. Over the past decade, hospitals have increasingly adopted electronic glycemic management systems (eGMSs) that use algorithms to automatically adjust insulin drip rates, replacing manual protocols guided by physician judgment and lab values. The appeal is intuitive: algorithms should deliver more consistent, safer insulin dosing. Yet direct evidence comparing these systems to conventional approaches remained scattered across small, non-randomized studies with differing designs and patient populations.

Researchers systematically reviewed seven studies totaling 3874 hospitalized patients to assess whether eGMSs actually improved outcomes. The primary outcome was time to DKA resolution, defined as when patients achieved normal blood pH, bicarbonate levels, and glucose control. Secondary outcomes included intensive care unit length of stay, hospital length of stay, duration of insulin infusion, and rates of hypoglycemia. The team applied rigorous meta-analytic methods with random-effects models to account for study heterogeneity.

The headline finding was neutral: eGMS-guided insulin infusion showed no statistically significant difference compared to conventional protocols for time to DKA resolution (standardized mean difference -0.04, 95% confidence interval -0.22 to 0.14). This means the pooled data could not detect a meaningful advantage for either approach. Similarly, ICU length of stay, hospital length of stay, and duration of insulin infusion showed no significant overall differences, though substantial heterogeneity across studies suggested variability in real-world performance.

One finding did lean toward eGMSs: recorded hypoglycemia was lower in automated system groups. However, the authors explicitly cautioned against over-interpreting this result. The studies showed serious-to-critical risk of bias, and the apparent hypoglycemia reduction could reflect differences in glucose-monitoring frequency, documentation practices, or detection bias rather than true clinical benefit. Some hospitals using eGMSs may have checked blood glucose more often, catching and treating low episodes more consistently, while conventional protocol groups had less frequent monitoring. This detection bias can artificially inflate hypoglycemia rates in the conventional group without indicating genuine safety superiority. The heterogeneity in results across studies (I2 = 74.8% for the primary outcome) further suggests that algorithmic differences, patient populations, and study quality created divergent findings that resist confident pooling.

What This Means for You

If you or a family member is hospitalized with diabetic ketoacidosis, the available evidence does not support choosing a hospital based on whether they use electronic insulin systems versus conventional protocols. Both approaches appear effective at resolving the acute metabolic crisis. The real determinants of outcome are likely rapid diagnosis, experienced ICU care, frequent monitoring regardless of whether algorithms or clinicians adjust insulin rates, and management of the underlying trigger (infection, missed insulin doses, new-onset diabetes).

The study underscores a broader principle in medicine: newer, automated systems sound safer in theory but require rigorous comparative testing. The absence of proven benefit does not mean eGMSs are harmful or unnecessary, only that high-quality randomized trials are needed before claiming superiority. If your hospital uses electronic glycemic management, this represents a reasonable tool; if it relies on experienced physicians and protocols, that is equally supported by current evidence.

For hospital administrators and clinicians, the takeaway is pragmatic: investment in eGMSs should be justified on grounds other than proven superiority in DKA outcomes. Cost, integration with existing electronic health records, staff training burden, and potential benefits in other patient populations (such as general critical care glucose control) may still favor adoption, but the case for DKA management specifically remains unproven.

Study Details

Sources

Bahjri K, et al. Electronic Glycemic Management Systems Versus Conventional Insulin Infusion Protocols in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis of Non-Randomized Studies. Medicina (Kaunas). 2025. PubMed.